Replimune (REPL) wins 10–3 FDA advisory vote on RP1 melanoma efficacy
Rhea-AI Filing Summary
Replimune Group, Inc. reported that the U.S. Food and Drug Administration’s Cellular, Tissue, and Gene Therapies Advisory Committee reviewed the Biologics License Application resubmission for RP1 (vusolimogene oderparepvec) plus nivolumab to treat advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
The committee examined whether the single-arm IGNYTE study reliably characterizes response rate and durability in the proposed population and whether the responses indicate systemic antitumor activity attributable to RP1. It then voted 10 to 3 that the IGNYTE efficacy results are evaluable and clinically meaningful.
Replimune’s CEO described the vote as an important step for patients with advanced melanoma and emphasized the unmet need for new options. The FDA’s target action date for the Class 1 resubmission is August 2, 2026. RP1 is an HSV-1–based oncolytic immunotherapy genetically armed with a fusogenic protein and GM-CSF to enhance tumor killing and systemic immune activation.
Positive
- FDA advisory panel backs RP1 efficacy data: The Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 that IGNYTE’s efficacy results for RP1 in advanced melanoma are evaluable and clinically meaningful, supporting continued regulatory review of the BLA.
- Near-term FDA decision timeline: The RP1 Biologics License Application resubmission has a Class 1 FDA target action date of August 2, 2026, providing a defined timeframe for a potential regulatory outcome.
Negative
- None.
Filing Explained
The 10-to-3 advisory-committee vote supports the disclosed efficacy finding, but it does not complete the regulatory review: the company says the FDA is still reviewing the BLA, with a target action date of
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Advisory Committee Vote: 10 to 3
FDA Target Action Date: August 2, 2026
Company founding year: 2015
3 metrics
Advisory Committee Vote
10 to 3
Vote that IGNYTE efficacy results for RP1 are evaluable and clinically meaningful
FDA Target Action Date
August 2, 2026
Class 1 resubmission BLA review for RP1 plus nivolumab in advanced melanoma
Company founding year
2015
Year Replimune Group, Inc. was founded
Key Terms
Biologics License Application, Cellular, Tissue, and Gene Therapies Advisory Committee, oncolytic immunotherapies, anti-PD-1 therapy, +1 more
5 terms
Biologics License Application regulatory
"discussed the Biologics License Application (BLA) resubmission for RP1"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
Cellular, Tissue, and Gene Therapies Advisory Committee regulatory
"FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)"
oncolytic immunotherapies medical
"a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies"
Oncolytic immunotherapies are treatments that use viruses or virus-like agents engineered to infect and destroy cancer cells while also waking up the immune system to attack tumors. Think of them as a Trojan horse that both breaks cancer’s defenses and calls in reinforcements; for investors, they matter because successful therapies can change standard cancer care, offer high commercial upside but come with steep scientific, regulatory and trial-stage risks that make outcomes binary and valuation-sensitive.
anti-PD-1 therapy medical
"for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy"
Anti-PD-1 therapy are drugs that block the PD-1 protein on immune cells, effectively releasing the “brakes” that can prevent the body from attacking cancer cells; think of it like removing a safety lock so security guards can better recognize intruders. Investors care because these therapies can transform treatment outcomes, drive significant sales if approved for multiple cancers, and carry regulatory, patent and competitive risks that affect a company’s valuation.
fusogenic protein medical
"genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did the FDA advisory committee conclude about Replimune (REPL) RP1 data?
The FDA’s advisory committee voted 10 to 3 that efficacy results from the single-arm IGNYTE study of RP1 in advanced melanoma are evaluable and clinically meaningful. The discussion focused on response rates, durability, and whether responses indicated systemic antitumor activity attributable to RP1.
Does the Replimune (REPL) advisory committee vote mean RP1 is approved by the FDA?
No. The vote means the committee found IGNYTE’s efficacy results clinically meaningful, but it is not an approval. The FDA continues reviewing the Biologics License Application for RP1 plus nivolumab and will make the final decision by its target action date.
When is the FDA target action date for Replimune (REPL) RP1 BLA resubmission?
The FDA’s target action date for the Class 1 resubmission of Replimune’s RP1 BLA is August 2, 2026. By this date, the agency aims to complete its review and decide whether to approve RP1 plus nivolumab for advanced melanoma after anti-PD-1 therapy.
For which patients is Replimune (REPL) seeking approval of RP1?
Replimune seeks approval of RP1 (vusolimogene oderparepvec) plus nivolumab for treating advanced melanoma in patients who have progressed on prior anti-PD-1 therapy. This population has a high unmet need, as highlighted by patient and physician comments at the advisory committee meeting.
What is RP1 and how is Replimune (REPL) developing it?
RP1 is an oncolytic immunotherapy based on a modified herpes simplex virus-1 backbone, armed with a fusogenic protein and GM-CSF. It is designed to maximize tumor killing and stimulate systemic anti-tumor immune responses, and is being developed with combinations such as nivolumab.
What clinical trial data supported Replimune (REPL) RP1 advisory committee discussion?
The discussion centered on the single-arm IGNYTE study of RP1 plus nivolumab in advanced melanoma. The committee evaluated whether the trial design allowed a reliable determination of expected response rate and durability, and whether responses showed systemic antitumor activity attributable to RP1.